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Casual blood pressure (CBP) measurements using
a standard sphygmomanometer have traditionally
constituted the principal modality for the diagno-
sis and management of hypertension. There is
substantial evidence, however, to suggest that CBP
determinations may not always reliably reflect
blood pressure (BP) at rest in other settings or
during ordinary daily activities. Apparently, casual
measurements of BP have shortcomings.1–3 In add-
ition to the rationale that BP varies widely and that
CBP measurements are unrepresentative of BP at
other times, the superiority of multiple BP meas-
urements rather than a single measurement in
pressure-related morbid events underlies the
value of noninvasive ambulatory blood pressure
monitoring (ABPM). Over the last three decades,
 ABPM has evolved from a research device to
an established and valuable clinical tool for as-
sessment and management of hypertension,4–10
although the technology remains underused. This
review is an attempt to increase clinicians’ under-
standing of ABPM and the appropriate use of this
technology. In the first part of this paper, I describe
the devices used in ABPM. Next, I summarize the
applications of ABPM and, finally, I mention the
problems in the use of ABPM.
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Casual blood pressure (CBP) measurements using a standard sphygmomanometer have traditionally consti-
tuted the principal modality for the assessment and management of hypertension. However, CBP measure-
ment has shortcomings. Ambulatory blood pressure monitoring (ABPM) provides abundant information on
blood pressure (BP), including heart rate, all BP readings for test periods, BP average, BP variability, BP load,
load index, distribution pattern of BP, reduction percentage of BP, trough/peak ratio, and summary statistics
 for overall 24-hour, daytime and nighttime periods. Over the last three decades, ABPM has evolved from
a research device to an established and valuable clinical tool for assessment and management of hyperten-
sion. This technology has been proven to be useful in terms of the distribution pattern of BP, characterization
of BP profiles in normotensive and hypertensive patients, evaluation of patients with mild or labile hyper-
ttension, physiologic and psychologic factors for fluctuation of BP, load index study, study of white coa
hypertension, etiology of hypertension, prognosis of hypertension, and assessment of antihypertensive man-
tagement. Nevertheless, the technology remains underused due to lack of insurance reimbursement in mos
countries. Accordingly, insurance reimbursement is crucial to promote increased utility of ABPM. Clinicians
should be familiar with the role of this technology in the care of patients with abnormal BP. This review is an
attempt to increase clinicians’ understanding of ABPM and the appropriate use of this technology. [J Formos
Med Assoc 2006;105(12):955–963]
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ABPM Devices and Items
Ambulatory BP monitors record BP by means of
oscillometric or auscultatory methods, or both.
Oscillometric monitors perceive arterial pressure
vibrations and calculate systolic and diastolic BPs
using an algorithmic approach. The readings can
be affected by arm movement but not background
noise. Auscultatory monitors detect the Korotkoff
sounds by using a microphone on the bladder cuff.
These monitors may be disturbed by background
noise but not arm movement. There are several
types of monitors that have been validated by the
British Hypertension Society and the Association
of Advancement of Medical Instrumentation.11
The examinee wears the ambulatory BP record
for a 24-hour period (Figure 1). BPs and heart
rates (HRs) are measured usually every 10–20
minutes during daytime hours and every 20–30
minutes during nighttime hours. The examinee
is instructed to keep a diary throughout the testing
period for evaluation of BP changes. The data are
analyzed with a microcomputer. The report pro-
vides abundant information on BP, including HR,
all BP readings for test periods, BP average, BP vari-
ability, BP load, load index, distribution pattern of
BP, reduction percentage of BP, trough/peak ratio,
and summary statistics for overall 24-hour, day-
time, and nighttime periods. Examples of ABPM
graphs are shown in Figure 2. Obviously, ABPM
can offer data on BP distribution and pattern that
cannot be obtained from CBP measurements.12–23
Applications of ABPM
ABPM has been proven to be useful in terms of the
distribution pattern of BP,15–23 characterization
of BP profiles in normotensive and hypertensive
patients,15–25 revaluation of patients with mild o
labile hypertension,25,26 physiologic and psycho-
logic factors for fluctuation of BP,12–14,27,28 load
index study,29,30 etiology of hypertension,31–36 prog-
nosis of hypertension,37–53 and assessment of anti-
hypertensive management.4,54–60 ABPM has been
increasingly used in the assessment of elevated
BP in addition to the diagnosis of hypertension.
Distribution pattern of BP
ABPM has demonstrated that normal people have a
BP pattern with suppression at nighttime.14–17,61,62
However, this normal circadian change in BP is
 not observed in certain groups of people, such
as some hypertensive patients,18,19,61,62 patients
with diabetes mellitus,63 cthose with autonomi
dysfunction63,64 or organ transplants65,66 or cere-
bral vascular accident.67,68 The abnormal circa-
dian change including non-dipping or reversed
circadian are associated with target organ com-
plications.42–45,49
White coat hypertension
yBP is a fluctuating variable that is influenced b
multiple physiologic and psychologic factors.
fTwenty-four-hour ABPM is more representative o
these factors.12–14,27,28 There are some people who
have persistently elevated clinic BPs but normal
pressures on ABPM. This effect of a physician on
BP is often referred to as white coat hypertension
(WCH).1,2,69 This phenomenon has been reported
in 15–35% of subjects currently labeled and treated
as hypertensive.1,70–72 The prevalence of WCH was
21% among our hospital population. Although
fcontroversy exists regarding the management o
WCH, most studies have suggested that it is a be-
nign condition.73–76 wWCH also represents a lo
risk stratum of Taiwanese with isolated office hyp-
ertension.77 Accordingly, identification of WCH is
of medical, social and economic importance. WCH
is most dramatically illustrated by using ABPM.
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iF gure 1. Examinee wearing the 24-hour ambulatory blood
pressure monitor.
Etiology and mechanism of hypertension
ABPM is also of great value in the investigation
of the etiology and mechanism of hypertension,
when it correlates other measurements with a
subject’s BP profile. Jefferies et al32 found that in-
creased nocturnal BP and reduced nocturnal BP
dipping may be risk factors for the later develop-
ment of hypertension in twins. Significant genetic
effects on both systolic BP and diastolic BP by
ABPM was found and estimates of genetic effects
were higher for daytime than nighttime ABPM
values.33 The interaction of adducing gene variants
(ADD1 and ADD3) in humans is statistically asso-
ciated with variation in ABPM values.34 Ramunni
and his colleagues35 suggested that factors other
than the renin–angiotensin system probably con-
tribute to the increase in renal vascular resistance
and to the early development of hypertension
evaluated by ABPM. Differences in peritoneal
transport properties were also demonstrated to
be associated with the development of hyperten-
sion in continuous ambulatory peritoneal dialysis
patients.36
Diagnosis of hypertension
ABPM is a highly useful diagnostic tool as it can
distinguish masked hypertension, WCH and sus-
tained hypertension. Therefore, the technology is
a more sensitive method for diagnosing hyperten-
csion than is sole reliance on office BP in chroni
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iF gure 2. fParameters o  
24-hour ambulatory blood
pressure (BP) monitoring: 
(A) distribution of ambulatory
BP; (B) histogram of BP.
renal disease patients and renal transplant recipi-
ents.78–80 Hypertension is linked to increased left
ventricular mass, stroke, cardiovascular morbidity
and mortality, and progression to end-stage renal
disease. ABPM is also a fundamental tool to diag-
nose resistant hypertension (RH) and to evaluate
treatment efficacy.81,82 True RH patients have more
target organ damage. The presence of a greater
pulse pressure and a lower nocturnal BP reduction
in true RH patients may be responsible for this
increased cardiovascular risk profile. Morning
periods have been associated with a greater risk for
cardiovascular events compared with the rest of the
24 hours. The morning surge in BP is believed to
contribute to the heightened risk and can only be
detected by ABPM.83
Mechanism of myocardial ischemia
ABPM is useful in load index study, which is imper-
ative for evaluating the mechanism of myocardial
ischemia.15 With Holter monitoring, the preva-
lence of silent myocardial ischemia in hypertensive
patients without coronary artery disease is between
25% and 73%. Silent myocardial ischemia result-
ing from increased oxygen demand remains to be
studied. The combined 24-hour Holter electrocar-
diography (ECG)/ABPM device is imperative.29
Nowadays, a new device allows simultaneous ST
segment analysis with extra BP recordings triggered
by episodes of ST segment depression and demon-
strated episodes of silent myocardial ischemia dur-
ing BP and HR increases in a study.30
Assessment of antihypertensive management
A relevant analogy to the use of Holter ECG mon-
itoring for evaluating response to antiarrhythmic
therapy is the use of ABPM for monitoring res-
ponse to antihypertensive medications. ABPM
has been used in the evaluation of the pharma-
cologically antihypertensive effects of various
antihypertensive agents, including monotherapy
or combination therapy,4,54–60 in special hyper-
tensive groups.63,84 This technology has also
been proven to be useful in the evaluation of anti-
hypertensive duration of long-acting antihyper-
tensive drugs. It has demonstrated that some
long-acting antihypertensive drugs cannot control
BP throughout the day or night or both periods.56
ABPM can provide the trough/peak ratio of vari-
ous antihypertensive drugs and, thus, the optimal
BP control.85,86 ABPM is also used to study the
mechanism of BP lowering effect.60
Prognostic implications
Another important use of ABPM is in the predic-
rtion of target organ damage and cardiovascula
morbidity. In every study in which ABPM has been
compared with CBP, ABPM has been shown to be
superior in predicting either target organ dam-
age38,42–47,50–53 or morbid events.37,39–41,48,49 In a
study,42 24-hour ABPM revealed a close relation-
ship between hypertensive target organ damage
t(ECG and chest roentgenographic evidence of lef
ventricular hypertrophy, proteinuria and retinopa-
thy) and the parameters of such measurements in
terms of BP pattern (reversed circadian pattern,
non-dip), comparisons between CBP and ambula-
tory BP (ABP) in addition to BP load and BP aver-
age. ABPM measurements such as BP pattern,
comparisons between CBP and ABP, and BP load
correlate more closely to the surrogates of cere-
brovascular (CVA) and cardiovascular disease than
office BP.67,68
Comparison between CBP and ABP
In normal conditions, ABP is lower than CBP. In
cases where ABP is higher than CBP, there was sig-
nificantly greater presence of target organ dam-
age or cardiovascular morbidity and mortality.42
A subject with reversed WCH—normal CBP and
yvariable fraction of abnormally high ABP—ma
have greater target organ damage than those with
normal ABP.87
Circadian rhythm
BP in normotensive subjects is characterized by a
clear circadian pattern, with values tending to
peak during the day but falling to a nadir at mid-
night. However, some hypertensive patients have 
a reversed circadian pattern where BP values fall
to a nadir during the day and reach a peak at mid-
night. The frequency of a reversed circadian rhythm
Y.Z. Tseng
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is significantly higher in patients with target organ
damage.42,48,49 Reversed circadian rhythm is found
more frequently in organ transplant recipients65,66
and patients with cerebral stroke.67,68 In acute CVA
disorders, the risk for loss of circadian change in
BP was strongly inversely correlated with the dis-
tance between the lesion and hypothalamus.68
Dipping
Verdacchia et al43 found that a nocturnal reduction
in systolic and diastolic BP of more than 10%
(dipping), could delay or prevent the develop-
ment of left ventricular hypertrophy. In contrast,
a nocturnal BP reduction of less than 10% of the
daytime value (non-dipping) was closely associ-
ated with target organ damage.42,45,49 In patients
with CVA disorder, there was a close correlation
between the distance from the lesion to the hypo-
thalamus and the ratio of nocturnal BP reduction
(circadian index). ABPM may be useful in localiza-
tion of the CVA lesion.68
Verification of hypertension in organ
transplant recipients
In renal transplant recipients, hypertension is com-
mon and associated with increased cardiovascular
and allograft rejection risks. Nocturnal hyperten-
sion is an underestimated phenomenon in this
population.78 The later serum creatinine correla-
ted positively with 24-hour systolic BP load and
ABPM-derived pulse pressure.88 However, BP con-
trol is not optimal in one-third of this population.
Therefore, ABPM is required for accurate diagnosis
and optimal treatment of hypertension to reduced
cardiovascular events in this population.72 ABPM
is also useful in evaluating the circadian rhythms
of BP in liver allograft recipients.66
Application in pediatrics
Varda and Gregoric89 suggested that ABPM is appli-
cable in the assessment of BP in very young chil-
dren. Wuhl et al90 found that ABPM provided
tsuperior information for diagnosis and treatmen
of pediatric hypertension. They suggested that nei-
ther CBP nor home BP detected hypertension with
enough sensitivity or specificity to replace ABPM.
ABPM is useful in evaluation of the relationship
between BP measured with ABPM and the progres-
sion of renal damage in normotensive children
with reflux nephropathy and in selecting children
at risk of hypertension.91
Problems in the Use of ABPM
Although ABPM is a useful modality for stratify-
cing cardiovascular risk and guiding therapeuti
decisions, the technology remains underused.
Problems hindering the widespread use of ABPM
include technology, the normal values of ABP, and
its cost-benefit.
Technology
A minority of examinees do not sleep well with
the records and tend to have somewhat unstable
BP values. Rarely, examinees may not be able to
tolerate the test or they may develop erythema in
the area distal to cuff placement. However, these
yproblems should disappear as the technolog
improves.92
Normal values of ABP
The definition of normal ABP remains to be estab-
lished. Many large population studies have been
carried out to define normal ABP (Table 1).93–96 All
fApplication o  ABPM
J Formos Med Assoc | 2006 • Vol 105 • No 12 959
Table 1. Ambulatory blood pressure of normotensive subjects
24-hr SBP/DBP (mmHg) Daytime SBP/DBP (mmHg) Nighttime SBP/DBP (mmHg)
O’Brien et al93 118 ± 11/72 ± 7 124 ± 12/78 ± 8 106 ± 11/61 ± 8
Imai et al94 118 ± 11/69 ± 7 121 ± 12/72 ± 7 106 ± 11/61± 7
Staessen et al95 116 ± 10/70 ± 7 122 ± 11/75 ± 8 106 ± 11/61 ± 8
Mancia et al96 118 ± 11/74 ± 7 123 ± 11/79 ± 8 108 ± 11/64 ± 8
SBP = systolic blood pressure; DBP = diastolic blood pressure.
of the studies have shown that ABP averages are
lower than CBP averages in normal subjects. Several
methods have also attempted to define the normal
values of ABP, with similar results. Table 2 shows
the diagnostic thresholds for ABPM currently
agreed on by the British Hypertension Society and
the American Society of Hypertension.8,93,95–97
Cost-benefit issues
The issue of cost-benefit is controversial. ABPM has
been considered to be an investigative technology
and its cost is not reimbursed in most countries.
This lack of reimbursement underlies the low use
of ABPM. Moser98 emphasized that ABPM per-
formed on hypertensive patients each year would
add to treatment expenditure, while other stud-
ies99,100 have shown that appropriate use of ABPM
does not increase the cost of care. Cost savings
would be found in people assessed with ABPM
compared with CBP measurement.55,99 In addi-
tion to lower cost of medications and physician
fees, reducing the unnecessary prescription of
medications for the highly prevalent WCH popu-
lation would be the most important source of
cost savings. More recently, the value of ABPM
has been recognized and it has been approved for
reimbursement by the center for Medicare and
Medicaid Services of the United States. Currently,
ABPM is only recommended for the evaluation of
WCH, patients with drug resistance, hypotension
with antihypertensive medications, episodic hyper-
tension and autonomic dysfunction.8 As ABPM
is still useful in identifying those who truly re-
quire antihypertensive therapy and those who
may best be managed with non-pharmacologic
therapy, reimbursement for ABPM is imperative.
Accordingly, national insurance coverage is crucial
to promote the increased clinical utility of ABPM.
fHowever, in case of widespread clinical use o
y ABPM, clinicians should use the technolog
judiciously.
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